ADVERUM BIOTECHNOGIES, INC.
100 Cardinal Way
Redwood City, California 94063-6548
April 28, 2023
VIA EMAILAND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3720
Washington, D.C. 20549
Attn: Doris Gama
| RE: | Adverum Biotechnogies, Inc. |
Registration Statement on Form S-3
File No. 333-271431
Ladies and Gentlemen:
Adverum Biotechnogies, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on May 2, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth Guernsey of Cooley LLP, counsel to the Registrant, at (415) 693-2091, or in his absence, Brett White at (650) 843-5191.
| Very truly yours, | ||
| ADVERUM BIOTECHNOGIES, INC. | ||
| By: | /s/ Linda Rubinstein | |
| Name: | Linda Rubinstein | |
| Title: | Chief Financial Officer | |
| cc: | John Rakow, General Counsel, Adverum Biotechnogies, Inc. |
Kenneth Guernsey, Cooley LLP
Brett White, Cooley LLP
